Highly validated immune marker and checkpoint antibodies to accelerate tumor microenvironment research.
Immuno-oncology has transformed how we treat many cancer types and provided hope for patients who receive advanced disease diagnoses. Unlike traditional cancer therapies that target tumor cells, immunotherapies stimulate the body’s immune system to eradicate tumor cells. Characterizing the types of immune cells present in the tumor microenvironment and profiling novel immune checkpoints are critical to advancing the field and developing novel immune therapies.
The relationship between a tumor and its microenvironment is fundamental to how cancer overrides normal cellular processes to proliferate. Recently, the most exciting therapies have involved clearing the immunosuppressive signals within the tumor using checkpoint inhibitors*. Successful inhibition of the PD-1 and CTLA-4 checkpoint pathways has revolutionized treatment, while discovering other receptor systems such as Tim-3, Lag-3, and OX40 has expanded the possibility of new checkpoint inhibitors.
Ongoing research in this field relies on dependable assay tools, such as antibodies that produce high quality, verifiable data in routine immuno-oncology applications. Browse an extensive catalog of rigorously validated recombinant antibodies for identifying immune-cell and tumor markers, T-cell markers and immune checkpoints. Bethyl antibodies are manufactured on-site and guaranteed to work in the intended application, including multiplex assay platforms.
Tumors suppress immune responses by the activation of negative signaling pathways termed immune checkpoints or co-inhibitory pathways. The ability of T-cells to mount an effective response is also dependent on the presence of co-stimulatory signaling. The characterization of the repertoire of inhibitory and stimulatory molecules can help determine the type of immunotherapy which will generate the most effective patient response.
The tumor microenvironment contains normal cells, tumor cells, lymphocytes, and blood vessels. The identification and interaction of these tumor microenvironment constituents aids in diagnostics, treatment and response measures.
The ability of the immune system to respond to cancer is dependent on T-cells specific for tumor-associated antigens. Both immune related cells and tumor cells can influence the activation state of T-cells. The ability to phenotype activation status and sub-categories of T-cells present in the tumor microenvironment is important for predicting immune response towards the tumor.
Quickly detect multiple antigens in a single tissue section to gain a clear understanding of the tumor microenvironment without compromising samples with Bethyl PathPlex®️ panels. Each antibody has been validated for immunohistochemistry (IHC) and utilized in a multiplex format by our scientists via proprietary processes to ensure the highest quality.
Core panels are listed below.
(*) Further Reading: